BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37336711)

  • 1. Established and novel circulating neuroendocrine tumor biomarkers for diagnostic, predictive and prognostic use.
    Tsoli M; Koumarianou A; Angelousi A; Kaltsas G
    Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101785. PubMed ID: 37336711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.
    Malczewska A; Kos-Kudła B; Kidd M; Drozdov I; Bodei L; Matar S; Oberg K; Modlin IM
    Adv Med Sci; 2020 Mar; 65(1):18-29. PubMed ID: 31841822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.
    Modlin IM; Bodei L; Kidd M
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):59-77. PubMed ID: 26971844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
    Liu E; Paulson S; Gulati A; Freudman J; Grosh W; Kafer S; Wickremesinghe PC; Salem RR; Bodei L
    Oncologist; 2019 Jun; 24(6):783-790. PubMed ID: 30158287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest.
    Kidd M; Kitz A; Drozdov I; Modlin I
    Neuroendocrinology; 2021; 111(5):490-504. PubMed ID: 32392558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
    van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
    Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review.
    Kalligeros M; Diamantopoulos L; Toumpanakis C
    Biology (Basel); 2021 Sep; 10(10):. PubMed ID: 34681049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
    Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
    Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
    Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors.
    Modlin IM; Kidd M; Malczewska A; Drozdov I; Bodei L; Matar S; Chung KM
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):485-504. PubMed ID: 30098712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
    Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease.
    Malczewska A; Bodei L; Kidd M; Modlin IM
    J Clin Endocrinol Metab; 2019 Mar; 104(3):867-872. PubMed ID: 30358858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NETest: A Systematic Review Focusing on the Prognostic and Predictive Role.
    Puliani G; Di Vito V; Feola T; Sesti F; Centello R; Pandozzi C; Tarsitano MG; Verrico M; Lenzi A; Isidori AM; Giannetta E; Faggiano A
    Neuroendocrinology; 2022; 112(6):523-536. PubMed ID: 34515175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
    Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
    Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis.
    Kidd M; Drozdov IA; Matar S; Gurunlian N; Ferranti NJ; Malczewska A; Bennett P; Bodei L; Modlin IM
    PLoS One; 2019; 14(6):e0218592. PubMed ID: 31247038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
    Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective.
    Mariën L; Islam O; Chhajlani S; Lybaert W; Peeters M; Van Camp G; Op de Beeck K; Vandamme T
    Curr Treat Options Oncol; 2023 Dec; 24(12):1833-1851. PubMed ID: 37989978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings.
    Giovanella L; La Rosa S; Ceriani L; Uccella S; Erba P; Garancini S
    Int J Biol Markers; 1999; 14(3):160-6. PubMed ID: 10569138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.